Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Nucana Plc ADR (NCNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 489,352
  • Shares Outstanding, K 32,226
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,470 K
  • 60-Month Beta 4.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.30
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -440.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.55 +21.00%
on 04/25/19
17.00 -10.68%
on 05/02/19
+2.47 (+19.38%)
since 04/24/19
3-Month
11.01 +37.92%
on 03/01/19
19.28 -21.24%
on 03/22/19
+3.48 (+29.68%)
since 02/22/19
52-Week
10.37 +46.43%
on 02/08/19
32.00 -52.55%
on 06/07/18
-12.48 (-45.12%)
since 05/24/18

Most Recent Stories

More News
NuCana Reports First Quarter 2019 Financial Results and Provides Business Update

Numerous Clinical Data Announcements and Study Initiations Expected in 2019

NCNA : 15.19 (+1.71%)
NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference

NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz, Chief Financial Officer,...

NCNA : 15.19 (+1.71%)
Will NuCana Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in NuCana.

NCNA : 15.19 (+1.71%)
NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update

Numerous Clinical Data Announcements and Study Initiations Expected in 2019

NCNA : 15.19 (+1.71%)
NuCana to Present at the Cowen and Company 39th Annual Health Care Conference

NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Hugh Griffith, Chief Executive...

NCNA : 15.19 (+1.71%)
NuCana to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019

NuCana plc (NASDAQ:NCNA) today announced that two abstracts related to NUC-3373 were selected for presentation at the AACR Annual Meeting 2019 to be held March 29 to April 3, 2019, in Atlanta, Georgia....

NCNA : 15.19 (+1.71%)
NuCana plc Announces Withdrawal of Public Offering of ADSs

EDINBURGH, United Kingdom, Jan. 25, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company (the "Company") focused on significantly improving treatment outcomes...

NCNA : 15.19 (+1.71%)
NuCana plc Announces Proposed Public Offering of ADSs

EDINBURGH, United Kingdom, Jan. 23, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with...

NCNA : 15.19 (+1.71%)
Amarin Down on Lower '19 View, Posts Preliminary '18 Results

Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.

AMRN : 17.63 (+2.03%)
MRUS : 13.14 (-2.60%)
NCNA : 15.19 (+1.71%)
MBRX : 1.11 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade NCNA with:

Business Summary

NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in...

See More

Key Turning Points

2nd Resistance Point 16.59
1st Resistance Point 15.89
Last Price 15.19
1st Support Level 14.60
2nd Support Level 14.01

See More

52-Week High 32.00
Fibonacci 61.8% 23.74
Fibonacci 50% 21.18
Fibonacci 38.2% 18.63
Last Price 15.19
52-Week Low 10.37

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar